Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Inclusion Criteria: 1. Males or females, aged \>18 years. 2. Patients with coronary artery disease who are scheduled for coronary intervention with bare metal stent placement for treatment of de novo or first restenosis in a native coronary artery. 3. Target lesion must be in a native coronary vessel of 2.25 - 4.0 mm size. 4. Target lesion has to be of less than or equal to 25 mm length. 5. Tandem lesion may be included as long as: * overall length is less than or equal to 25 mm * tandem lesion will be treated with one stent and counted as one lesion. Exclusion Criteria: The following exclusion criteria must not be present at Baseline visit 1 (BL1, Screening visit prior to coronary intervention). If an exclusion criterion occurred afterwards, e.g., during the coronary intervention, the patient must be excluded from the study. 1. Target lesion has a reference vessel size of less than 2.25 or more than 4.0 mm diameter. 2. Target lesion is a total occlusion or located at a bifurcation. 3. Treatment affords implantation of more than one stent per treated lesion. 4. Target lesion was already treated by brachytherapy. 5. Target lesion has one or more of the following criteria: * Left main lesion * Ostial lesion of the RCA * Located at less than 2 mm after the origin of the LAD or RCX. Other protocol defined inclusion/exclusion criteria may apply.